Sign in
CompletedPhase 1

PK Effects of SHR4640 on Repaglinide and Midazolam, and the Impact of SHR4640 on QT Interval

Key facts

Who runs it
Jiangsu HengRui Medicine Co., Ltd.
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 1
People taking part
24 people enrolled
Started
4 Jan 2024
Ended
16 Feb 2024
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • repaglinide; midazolam; SHR4640
  • repaglinide; midazolam; SHR4640; SHR4640 placebo
  • repaglinide; midazolam; SHR4640 placebo
Record updated
6 March 2024

Who can take part

Age
18 years to 45 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 25 criteriaShow less

Who can take part

  • Voluntarily sign the informed consent form before the start of the trial-related activities, and be able to understand the procedures and methods of the trial, and are willing to strictly comply with the clinical trial protocol to complete the trial
  • Aged 18 to 45 years old (both ends included, subject to the time of signing the informed consent form), male or female
  • Male weight ≥ 50 kg, female weight ≥ 45 kg, and body mass index (BMI): 19-26 kg/m2 (both ends included)
  • No fertility plan and agree to take non-drug high-efficiency contraceptive measures (see appendix 1 for details) within 28 days from signing the informed consent form to the last administration of the trial drug, and no plans for sperm donation or egg donation

Who cannot take part

  • Individuals who have a history of smoking within the 3 months before signing the informed consent form (average daily smoking>5 cigarettes) or who cannot stop using any tobacco products during the study period
  • The average daily intake of alcohol in the three months before signing the informed consent is more than 7 g for women (about 200 ml beer, 70 ml wine or 22 ml low-alcohol liquor) and 14 g for men (about 400 ml beer, 140 ml wine or 45 ml low-alcohol liquor); Those who cannot abstain from alcohol during the trial
  • Within the first 7 days of randomization, consumed any beverage or food containing grapefruit; Or have eaten any beverages or foods containing methylxanthines, such as coffee, tea, cola, chocolate, etc., within the previous 2 days at random
  • Drug abusers, or those who have positive urinary abuse during screening
  • Individuals who have used any prescription drugs, over-the-counter drugs, herbal medicines, or dietary supplements within two weeks before randomization
  • Systemic treatment with cytochrome P450 3A4 enzyme (CYP3A4), CYP2C8 inhibitor or inducer drugs used within the first 4 weeks of randomization
  • Individuals (excluding screening failures) who have participated in any other drug or medical device clinical trials within 3 months before randomization or within 5 half-lives of the trial drug (whichever is longer)
  • Individuals who have undergone any surgery within three months before randomization, or have not recovered after surgery, or plan to undergo surgery during the trial
  • Individuals who have donated (or lost) blood within three months before randomization and the amount of blood donated (or lost) is ≥400 mL, or received blood transfusion
  • Allergic constitution, or allergic or suspected allergic to SHR4640 tablets, repaglinide or midazolam
  • any history of severe clinical disease or conditions that the researcher believes may affect the results of the trial, including but not limited to the history of circulatory, endocrine, nervous, digestive, urinary, or blood, immune, psychiatric, and metabolic diseases
  • Patients with contraindication of repaglinide (type 1 diabetes, C-peptide negative diabetes patients, diabetes ketoacidosis patients with or without coma)
  • Patients with contraindications to midazolam (acute angle closure glaucoma, severe respiratory insufficiency, sleep apnea syndrome, myasthenia gravis, schizophrenia, and severe depressive state)
  • Individuals with positive hepatitis B surface antigen (HBsAg), or anti-hepatitis C virus (HCV) antibodies, or human immunodeficiency virus (HIV) antibodies, or syphilis antibodies during screening
  • According to the judgment of the researchers, subjects with conditions that affect drug absorption, distribution, metabolism, and excretion, or other factors that are not suitable for participation in the study
  • During screening, vital signs, physical examinations, laboratory tests, cardiac ultrasound, abdominal ultrasound, or chest imaging examinations indicate the presence of abnormalities that are clinically significant according to the judgment of the investigator
  • Individuals with serum uric acid higher than 420 μmol/L at screening, , or a history of hyperuricemia and/or gout disease
  • Individuals with risk factors for torsade de pointe ventricular tachycardia, such as heart failure, hypokalemia, short QT syndrome, long QT syndrome, or a first-degree relatives family history of unexplained sudden death, drowning, or sudden infant death syndrome in young adulthood (≤ 40 years old)
  • When screening, ultrasound examination of the urinary system indicates the presence of stones or crystals in the urinary system
  • Individuals with acute kidney injury before screening or random
  • Individuals with QTcF>450 ms, PR interval>200 ms, QRS complex time limit>120 ms, or HR>100 bpm, or other abnormalities that were clinically significant as determined by the researcher

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The purpose of this study is to evaluate the PK effects of SHR4640 tablets on repaglinide and midazolam, as well as the effects of SHR4640 tablets on the QT interval in healthy subjects.

The 3 groups in the trial

  • SHR4640 group ATreatment being tested

    Treatment: repaglinide; midazolam; SHR4640

  • SHR4640 group BTreatment being tested

    Treatment: repaglinide; midazolam; SHR4640; SHR4640 placebo

  • SHR4640 PlaceboPlacebo, for comparison

    Treatment: repaglinide; midazolam; SHR4640 placebo

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Clinical Study Evaluating the Pharmacokinetic Effects of SHR4640 on Repaglinide and Midazolam in Healthy Subjects and the Impact of SHR4640 on QT Interval
Record updated
6 March 2024